B1

General Information


DRACP ID  DRACP00714

Peptide Name   B1

Sequence  KKLFKKILKYLK

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  antimicrobial peptides

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=15.7±1.5 μM MTT assay 48h 1
MCF-7/ADM Invasive breast carcinoma of no special type Carcinoma IC50=18.2±1.3 μM MTT assay 48h 1
K562 Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia Leukemia IC50=17.9±1.4 μM MTT assay 48h 1
K562/Adr Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia Leukemia IC50=19.1±2.1 μM MTT assay 48h 1

Hemolytic Activity  Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3)

Normal (non-cancerous) Cytotoxicity  GES-1: IC50=52.3±4.5 μM

Target  Not available

Affinity  Not available

Mechanism  disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis

Nature  Anticancer; Antitumor; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00714

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C78H136N18O14

Absent amino acids  ACDEGHMNPQRSTVW

Common amino acids  K

Mass  174644

Pl  11.13

Basic residues  6

Acidic residues  0

Hydrophobic residues  5

Net charge  6

Boman Index  -1078

Hydrophobicity  -50

Aliphatic Index  130

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  135.45

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 28524273

Title  Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities

Doi 10.1111/cbdd.13023

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.